Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 102, Issue 3, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2021.115597
Keywords
Vaccine; Immunization; Public health; Immunoglobulin G; CoronaVac; Pandemic
Categories
Funding
- PROPLAN/Federal University of Parana, Curitiba-Parana, Brazil
- FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 [0494/20]
Ask authors/readers for more resources
This study aimed to evaluate the immunogenicity of the CoronaVac vaccine in healthcare workers. The results showed a high seroconversion rate of the vaccine in this population.
This study aimed to calculate the seroconversion rate and IgG antibody dynamic range of the CoronaVac vaccine in healthcare workers (HCWs) after immunization. Serum samples from 133 HCWs from Southern Brazil were collected 1 day before (Day 0) and +10, +20, +40, + 60, +110 days after administering the vaccine's first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein (nucleocapsid) antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lubeck, Germany). Seroconversion by day 40 occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in 2 (1.5%) HCWs undergoing semi-annual rituximab administration, and also in another 2 (1.5%) HCWs with no apparent reason. This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population. (C) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
